This study, led by N2CR members Dr Joline Lim and A/Prof David Tan, looks at the use of next-generation sequencing (NGS) for molecular profiling of metastatic breast cancer (MBC) in Asian patients. NGS identified actionable mutations, enabling targeted therapy. The PI3K/AKT/PTEN pathway was most altered. Matched treatment improved progression-free survival and overall survival. The study concludes that broad-panel NGS in MBC is feasible and beneficial.

Read more here: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1342346/full